1.	Stereotactic Body Radiotherapy for Head and Neck Tumors Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 08-046, NCT01344356
2.	Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00507, E1305, CDR0000582533, U10CA021115, ECOG-E1305, NCT00588770
3.	Study to Compare the Overall Survival of Patients Receiving INGN 201 (Study Drug) With Patients Receiving Methotrexate Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: T301, INTROGEN-T301, NCT00041613
4.	Effectiveness and Safety of INGN 201 in Combination With Chemotherapy Versus Chemotherapy Alone Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: T302, INTROGEN-T302, UCLA-0312111-01, NCT00041626
5.	Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000675520, NCCTG-N09C6, N09C6, NCT01156142
6.	Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 06-121, 1R21CA130241-01A1, NCT00903461
7.	Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GCO # 06-0509, NCT00970502
8.	Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC) Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 09-131, NCT01016769
9.	Study of PX-866 and Docetaxel in Solid Tumors Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PX-866-002, NCT01204099
10.	A Clinical Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: BBI608-201, NCT01325441
11.	A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CBYL719X2104, 2011-006017-34, NCT01602315
12.	Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes Phase: Phase II Type: Treatment Status: Active Age: 10 and over Sponsor: Other Protocol IDs: 25145-CADEN, CADEN, NCT00953420
13.	A Multi-Histology Phase II Study of 5-Fluoro-2-Deoxycytidine With Tetrahydrouridine (FdCyd + THU) Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 090214, 09-C-0214, NCT00978250
14.	A Study in Head and Neck Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 13420, I4E-MC-JXBB, NCT01063075
15.	Study in Head and Neck Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 13418, I4E-MC-JXBA, NCT01099358
16.	Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UPCI 06-093, NCT01104922
17.	Randomized Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck Phase: Phase II Type: Treatment Status: Active Age: 18 to 89 Sponsor: Other Protocol IDs: 10-069-B, NCT01133678
18.	Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2011-02556, PHL-068, N01CM62203, N01CM00032, N01CM00038, PMH-PHL-068, 8192, NCT01267240
19.	Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2011-02596, 10-428-B, CDR0000689896, UCCRC-10-428-B, N01CM00099, N01CM00071, 8692, NCT01256385
20.	Akt Inhibitor MK2206 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2011-02581, MC1079, CDR0000696863, N01CM00099, MAYO-MC1079, 8761, NCT01349933
21.	Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and ovwe Sponsor: Other Protocol IDs: FER-HN-027, NCI-2011-00272, NCT01316757
22.	Weekly Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN) Phase: Phase II Type: Treatment Status: Active Age: 16 and over Sponsor: Other Protocol IDs: ENT0033, SU-08222011-8290, 22329, NCI-2011-03271, NCT01437449
23.	Phase II Trial Evaluating Axitinib In Patients With Unresectable, Recurrent Or Metastatic Head And Neck Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UMCC 2011.053, HUM00051095, NCT01469546
24.	Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 08-034, CA180264, NCT01488318
25.	Therapeutic Effects Of Epstein-Barr Virus Immune T-Lymphocytes Derived From A Normal HLA- Compatible Or Partially- Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies Phase: Phase II Type: Diagnostic, Treatment Status: Active Age: any age Sponsor: Other Protocol IDs: 11-130, NCT01498484